Could GW Pharmaceuticals plc (GWPH) Rise Even More? The Stock Had Another Big Increase Today

December 7, 2017 - By Maria Brooks

The stock of GW Pharmaceuticals plc (NASDAQ:GWPH) is a huge mover today! The stock increased 7.73% or $8.97 during the last trading session, reaching $124.97. About 1.22M shares traded or 223.85% up from the average. GW Pharmaceuticals plc (NASDAQ:GWPH) has risen 31.90% since December 7, 2016 and is uptrending. It has outperformed by 15.20% the S&P500.
The move comes after 9 months positive chart setup for the $3.17 billion company. It was reported on Dec, 7 by Barchart.com. We have $131.22 PT which if reached, will make NASDAQ:GWPH worth $158.50 million more.

GW Pharmaceuticals plc (NASDAQ:GWPH) Ratings Coverage

Among 13 analysts covering GW Pharmaceuticals (NASDAQ:GWPH), 11 have Buy rating, 1 Sell and 1 Hold. Therefore 85% are positive. GW Pharmaceuticals had 22 analyst reports since August 13, 2015 according to SRatingsIntel. The stock has “Buy” rating by Cantor Fitzgerald on Monday, September 26. Roth Capital maintained GW Pharmaceuticals plc (NASDAQ:GWPH) rating on Monday, March 14. Roth Capital has “Buy” rating and $160 target. Bank of America maintained GW Pharmaceuticals plc (NASDAQ:GWPH) on Tuesday, November 14 with “Buy” rating. Maxim Group maintained the stock with “Buy” rating in Thursday, June 8 report. Roth Capital initiated it with “Buy” rating and $130 target in Monday, November 30 report. The company was initiated on Thursday, August 13 by Morgan Stanley. As per Friday, June 3, the company rating was initiated by Cantor Fitzgerald. The firm earned “Buy” rating on Thursday, October 26 by Cowen & Co. Piper Jaffray maintained the stock with “Buy” rating in Thursday, August 3 report. Evercore initiated the stock with “Buy” rating in Wednesday, August 16 report.

More notable recent GW Pharmaceuticals plc (NASDAQ:GWPH) news were published by: Investorplace.com which released: “GW Pharmaceuticals PLC- ADR (GWPH) Stock Is High-Risk, High Reward” on August 18, 2017, also Investorplace.com with their article: “Get Long GW Pharmaceuticals PLC- ADR (GWPH) Stock for Free” published on July 12, 2017, Investorplace.com published: “GW Pharmaceuticals PLC- ADR (GWPH) Stock Is Just Getting Started” on December 06, 2016. More interesting news about GW Pharmaceuticals plc (NASDAQ:GWPH) were released by: Investorplace.com and their article: “Get Long GW Pharmaceuticals PLC- ADR for Free” published on December 04, 2017 as well as Benzinga.com‘s news article titled: “Is GW Pharma Now The Future Of Cannabis-Based Drugs?” with publication date: August 08, 2017.

GW Pharmaceuticals plc, a biopharmaceutical company, engages in discovering, developing, and commercializing cannabinoid prescription medicines using botanical extracts derived from the Cannabis plant. The company has market cap of $3.17 billion. It operates through three divisions: Commercial, Sativex Research and Development, and Pipeline Research and Development. It currently has negative earnings. The firm markets Sativex, an oromucosal spray for the treatment of spasticity due to multiple sclerosis.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.